Research programme: therapeutic antibodies - ICOS / Dyax
Latest Information Update: 24 Mar 2009
At a glance
- Originator Dyax
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 29 Jan 2007 ICOS Corporation has been acquired by Eli Lilly
- 24 May 2006 Preclinical trials in Undefined in USA (unspecified route)